The data previously reported from the STAMPEDE trial and the LATITUDE trial over the past couple of days were from men newly diagnosed with high-risk and/or metastatic forms of prostate cancer, but … They raise an interesting new question that only occurred to your sitemaster this morning, and which has never came up in any […]![]()
